According to relevant data, it is expected that by 2025, the global biopharmaceutical market will grow to 530.1 billion US dollars, and the size of the Chinese biopharmaceutical market will increase to 811.6 billion yuan. According to other data, the global market size for biopharmaceutical equipment and consumables was approximately $18.7 billion in 2020, and it is expected that the global equipment and consumables market will continue to grow by 8% -10% in the next five years. In this context, some domestic pharmaceutical equipment and consumables suppliers with strong capabilities are actively seizing opportunities and emerging on the international stage.

 

 

 

On July 4th, InnoCellular Tech Pte Ltd (referred to as InnoCellular), a Singaporean company invested by Abbott Biotech Co., Ltd. (referred to as "Abbott"), made a dazzling appearance at the EVANTICA seminar, attracting industry attention.

 

 

 

At the meeting, InnoCelluar announced the joint launch of research and development work on a new project with the EVANTICA research team. The EVANTICA research team is committed to improving the specificity and amplification efficiency of extracellular vesicles (EVs) derived from mesenchymal stem cells through engineering modifications, providing a groundbreaking new approach for cancer treatment. The new project aims to develop an innovative anti-cancer therapy platform technology based on extracellular vesicles from mesenchymal stem cells. The team of scientists will use Aibeitai's self-developed bioreactor and InnoCellular mesenchymal stem cell specific culture medium for large-scale expansion of MSCs to obtain extracellular vesicles.

 

 

 

Public information shows that Aibeitai is committed to providing professional production and analysis equipment, disposable consumables, and overall solutions for the biopharmaceutical industry. Since its establishment, the company has always been customer-centric, with "quality first, service first" as its business policy. Based on the optimization, scaling up, and production of biological processes, it continuously improves its product line in the biopharmaceutical field, provides users with comprehensive professional solutions for biological processes, and helps users continuously make new breakthroughs in the biopharmaceutical field.

 

 

 

In the field of bioreactors, Aibeitai has been deeply involved for many years and is committed to creating high-end independent bioreactors. At present, its bioreactors cover multiple fields including research and development, pilot testing, and cGMP production, and are widely used in the research and production of antibodies, vaccines, cell therapy, gene therapy, and stem cell therapy. With bioreactors as the core business, the company has gradually formed a product layout covering process detection, spectral analysis, cell analysis, online sampling, sample processing, etc., providing a wide range of products and technical services for domestic and foreign biopharmaceutical enterprises. The application of Aibeitai's self-developed bioreactor in this new project is a recognition of the company's product strength.

 

 

 

It is reported that previously, Aibeitai and InnoCellular had reached a technological strategic cooperation, and Aibeitai bioreactors combined with InnoCellular culture medium were used for multiple MSC amplification experiments. The data shows that the amplification efficiency of MSCs is at least twice that of traditional culture media, demonstrating the performance of their respective products.

 

 

 

The strong alliance between Abetai, InnoCellular, and EVANTICA marks an important step forward in the field of novel cancer treatment. The three parties will work together to launch the next generation of highly efficient targeted anti-cancer therapies, bringing better treatment options to patients.